Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer

Abstract

Aim: The current study aims to investigate the critical role of the focal adhesion kinase (FAK) oncogenic signaling pathway in mediating drug resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) and evaluate the potential of two novel FAK inhibitors, 10k and 10l, as therapeutic strategies for drug resistant non-small cell lung cancer (NSCLC).

Methods: EGFR-TKI resistance in NSCLC cells was developed via stepwise drug selection. Kinases/polymerase chain reaction (PCR) arrays identified key resistance determinants, while reverse transcription quantitative polymerase chain reaction (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry evaluated FAK messenger RNA and phosphorylation levels. Antitumor activities were assessed using sulforhodamine-B, clonogenic, wound-healing, and apoptosis assays, spheroids and xenografts.

Results: FAK was identified as a key driver of acquired resistance to EGFR-TKIs. High FAK expression predicted poor prognosis in patients treated with EGFR-TKIs. Kinase and PCR profiling confirmed elevated FAK levels as a resistance mechanism. Compounds 10k and 10l reduced phosphorylated FAK and showed strong anti-proliferative, anti-migratory, and pro-apoptotic effects in both EGFR-TKI-sensitive and -resistant cells. Notably, these compounds were shown to resensitize resistant NSCLC cells to EGFR-TKIs, with 10k inhibiting tumor growth and enhancing Osimertinib efficacy in resistant xenografts.

Conclusion: These findings not only uncover a pivotal mechanism of EGFR-TKI drug resistance but also highlight innovative, promising therapeutic options for patients with therapy-refractory disease.

Keywords

Focal adhesion kinase (FAK) / EGFR-TKI resistance / non-small cell lung cancer (NSCLC) / Afatinib / Osimertinib

References

[1] Bray F,Sung H.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024;74:229-63

[2] Miao D,Han Y.Management of locally advanced non-small cell lung cancer: state of the art and future directions.Cancer Commun2024;44:23-46 PMCID:PMC10794016

[3] Corvaja C,Attili I.Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: bridging biological insights and therapeutic development.Cancer Treat Rev2024;130:102824

[4] Liang SK,Hsieh MS,Shih JY.Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib.ERJ Open Res2024;10:00676-2023 PMCID:PMC10945387

[5] Piper Vallillo AJ, Viray H, Feldman J, Rangachari D. Management of treatment resistance in patients with advanced epidermal growth factor receptor-mutated lung cancer: personalization, parsimony, and partnership.J Clin Oncol2024;42:1215-21

[6] Nicoś M,Kalinka E.Possibilities of overcoming resistance to osimertinib in NSCLC patients with mutations in the EGFR gene.Cancers2025;17:563 PMCID:PMC11852969

[7] Li Y,Finley C.Current and future treatment options in the management of stage III NSCLC.J Thorac Oncol2023;18:1478-91

[8] Li X,Salaita K.Polarized focal adhesion kinase activity within a focal adhesion during cell migration.Nat Chem Biol2023;19:1458-68 PMCID:PMC10732478

[9] Hu HH,Shang HL.Roles and inhibitors of FAK in cancer: current advances and future directions.Front Pharmacol2024;15:1274209 PMCID:PMC10895298

[10] Shi Y,Zhang Y,Sun X.Comprehensive pan-cancer analysis of 33 human cancers reveals immunotherapeutic value of focal adhesion tyrosine kinase.Medicine2024;103:e37362 PMCID:PMC10956984

[11] Yang M,Luo G.Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders.Biochem Pharmacol2024;224:116246

[12] Chuang HH,Tsai YC.FAK in cancer: from mechanisms to therapeutic strategies.Int J Mol Sci2022;23:1726 PMCID:PMC8836199

[13] Tozuka T,Yoshida K.Phosphoproteomic analysis identified mutual phosphorylation of FAK and Src as a mechanism of osimertinib resistance in EGFR-mutant lung cancer.JTO Clin Res Rep2024;5:100668 PMCID:PMC11031815

[14] Haderk F,Cech L.Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.Nat Commun2024;15:3741 PMCID:PMC11068778

[15] Kosibaty Z,Zwicky Eide IJ.Ras-related protein Rab-32 and thrombospondin 1 confer resistance to the EGFR tyrosine kinase inhibitor osimertinib by activating focal adhesion kinase in non-small cell lung cancer.Cancers2022;14:3430 PMCID:PMC9317954

[16] Fu Y,Lei Z.Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.J Hematol Oncol2020;13:169 PMCID:PMC7720454

[17] Aboubakar Nana F,Ambroise J.Increased expression and activation of FAK in small-cell lung cancer compared to non-small-cell lung cancer.Cancers2019;11:1526 PMCID:PMC6827365

[18] Dy GK,Pokharel S.The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.J Thorac Oncol2014;9:1278-84 PMCID:PMC4133746

[19] Ocak S,Callison C,Massion PP.Expression of focal adhesion kinase in small-cell lung carcinoma.Cancer2012;118:1293-301 PMCID:PMC3673887

[20] Banerjee S,Greystoke A.Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial.Nat Med2025;31:3074-80 PMCID:PMC12443583

[21] Zhu SK,Liu GX,Wang PA.Recent advances in focal adhesion kinase (FAK)-targeting antitumor agents.RSC Adv2025;15:20957-84 PMCID:PMC12180522

[22] Fennell DA,Taylor P.Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-A double-blind, randomized, phase II study.J Clin Oncol2019;37:790-8

[23] Gerber DE,Morgensztern D.Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.Lung Cancer2020;139:60-7 PMCID:PMC6942685

[24] Pecoraro C,Scianò F.Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: synthesis, mechanistic insights and promising antitumor and safety profile.J Drug Target2024;32:1278-94

[25] Sciarrillo R,Kooi IE.Using RNA-sequencing to detect novel splice variants related to drug resistance in in vitro cancer models.J Vis Exp2016;9:54714 PMCID:PMC5226372

[26] Bijnsdorp IV,Peters GJ.Analysis of drug interactions. In: Cree IA, editor. Cancer cell culture. Totowa: Humana Press; 2011. pp. 421-34.

[27] Churchman ML,Richmond J.Synergism of FAK and tyrosine kinase inhibition in Ph⁺ B-ALL.JCI Insight2016;1:86082 PMCID:PMC4844070

[28] Ichihara E,Meador CB.SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer.Cancer Res2017;77:2990-3000 PMCID:PMC5467531

[29] Zhou X,Huang Z.Strategies beyond 3rd EGFR-TKI acquired resistance: opportunities and challenges.Cancer Med2025;14:e70921 PMCID:PMC12051098

[30] Gershon D.Cell signalling: making connections.Nature2004;432:243-9

[31] Angelopoulos PA,Attili I.Management of MET-driven resistance to osimertinib in EGFR-mutant non-small cell lung cancer.Genes2025;16:772 PMCID:PMC12294663

[32] Hu D,Lei S,Wang Y.MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis.BMC Cancer2025;25:732 PMCID:PMC12007359

[33] Wang QA,Lin CY.Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study.Ther Adv Med Oncol2025;17:17588359251321901 PMCID:PMC11907550

[34] Viray H,Widick P.A real-world study of patient characteristics and clinical outcomes in EGFR mutated lung cancer treated with first-line osimertinib: expanding the FLAURA trial results into routine clinical practice.Cancers2024;16:1079 PMCID:PMC10968877

[35] Groenendijk FH.Drug resistance to targeted therapies: déjà vu all over again.Mol Oncol2014;8:1067-83 PMCID:PMC5528618

[36] Jin H,Bernards R.Rational combinations of targeted cancer therapies: background, advances and challenges.Nat Rev Drug Discov2023;22:213-34

[37] Levy A,Dondapati P.Focal adhesion kinase in ovarian cancer: a potential therapeutic target for platinum and taxane-resistant tumors.Curr Cancer Drug Targets2019;19:179-88

[38] Zhang Y,Boyer A.Nuclear focal adhesion kinase protects against cisplatin stress in ovarian carcinoma.Cancer Res Commun2024;4:3165-79 PMCID:PMC11659947

[39] Cavazzoni A,Alfieri R.Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.Oncotarget2017;8:53068-83 PMCID:PMC5581093

[40] Li L,Lu C.Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling.Commun Biol2022;5:155 PMCID:PMC8866396

[41] Vengoji R,Nimmakayala RK.Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.J Exp Clin Cancer Res2019;38:266 PMCID:PMC6582495

[42] Assaraf YG,Gonçalves AC.The multi-factorial nature of clinical multidrug resistance in cancer.Drug Resist Updat2019;46:100645

[43] Du Z,Sun J.Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.Drug Resist Updat2025;82:101266

[44] Kaloni D,Strasser A.BCL-2 protein family: attractive targets for cancer therapy.Apoptosis2023;28:20-38 PMCID:PMC9950219

[45] Alam M,Shamsi A.Bax/Bcl-2 cascade is regulated by the EGFR pathway: therapeutic targeting of non-small cell lung cancer.Front Oncol2022;12:869672 PMCID:PMC8990771

[46] Vogler M,Smith VM.The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy.Signal Transduct Target Ther2025;10:91 PMCID:PMC11926181

[47] Deng J,Perera S.Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.Cancer Res2007;67:11867-75

[48] Luo QY,Di T.The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer.Acta Pharmacol Sin2025;46:1082-96 PMCID:PMC11950313

[49] Fan X,Wu H.STAT3 mediates CAF-induced osimertinib resistance via regulating protein secretion in non-small cell lung cancer.Front Pharmacol2025;16:1546491 PMCID:PMC12283998

[50] Amato KR,Tan L.EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer.Cancer Res2016;76:305-18 PMCID:PMC4715957

[51] Bononi G,Poli G.Reversible monoacylglycerol lipase inhibitors: discovery of a new class of benzylpiperidine derivatives.J Med Chem2022;65:7118-40 PMCID:PMC9150076